X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - THEINDIANSUN.COM.AU - A La Une - 18/Sep 00:00

Monash therapy advances to Phase 3 breast cancer trials

A therapy discovered in Melbourne has moved into Phase 3 clinical trials, a milestone rarely reached by Australian research. Pfizer has begun studying PF-07248144, a potential treatment for HR+, HER2- advanced or metastatic breast cancer, developed from work at Monash University and the Cancer Therapeutics Cooperative Research Centre (CTx). The medicine targets proteins KAT6A and […]

Articles similaires

Sorry! Image not available at this time

DelveInsight Metastatic Breast Cancer Pipeline Drugs Report 2025: Drugs, Clinical Trials, Treatment Strategies, and Companies ...

wn.com - 29/Sep 19:17

DelveInsight’s “Metastatic Breast Cancer Pipeline Insights 2025” report provides comprehensive insights about 100+ companies and...

Sorry! Image not available at this time

FDA Approves INLURIYO (Imlunestrant): A Game-Changer for ESR1-Mutated Metastatic Breast Cancer Treatment | DelveInsight’s Perspective

wn.com - 27/Sep 02:02

"FDA approved INLURIYO (imlunestrant) by Eli Lilly, on September 25, 2025" The pharmaceutical landscape for metastatic breast cancer treatment has...

Sorry! Image not available at this time

FDA Approves INLURIYO (Imlunestrant): A Game-Changer for ESR1-Mutated Metastatic Breast Cancer Treatment | DelveInsight’s Perspective

wn.com - 27/Sep 02:02

"FDA approved INLURIYO (imlunestrant) by Eli Lilly, on September 25, 2025" The pharmaceutical landscape for metastatic breast cancer treatment has...

Sorry! Image not available at this time

FDA Approves Inluriyo (imlunestrant) for Adults with ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

drugs.com - 25/Sep 20:09

INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has...

Sorry! Image not available at this time

FDA Approves Inluriyo (imlunestrant) for Adults with ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

drugs.com - 25/Sep 20:09

INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has...

Sorry! Image not available at this time

NATALEE 4-year data: Ribociclib extends recurrence-free survival in early breast cancer

oncologynews.com.au - 29/Sep 05:21

Hormone receptor (HR)–positive, ERBB2 (formerly HER2)–negative breast cancer is the most common subtype, accounting for more than 70% of cases....

Sorry! Image not available at this time

NATALEE 4-year data: Ribociclib extends recurrence-free survival in early breast cancer

oncologynews.com.au - 29/Sep 05:21

Hormone receptor (HR)–positive, ERBB2 (formerly HER2)–negative breast cancer is the most common subtype, accounting for more than 70% of cases....

Sorry! Image not available at this time

FDA Approves New Therapy for Advanced Breast Cancer

wn.com - 26/Sep 14:58

The Food and Drug Administration on Sept. 25 approved a new therapy for advanced breast cancer, based on data from a phase...

Sorry! Image not available at this time

FDA Approves New Therapy for Advanced Breast Cancer

wn.com - 26/Sep 14:58

The Food and Drug Administration on Sept. 25 approved a new therapy for advanced breast cancer, based on data from a phase...

Sorry! Image not available at this time

Breast Cancer Pipeline Drugs Report 2025 by DelveInsight Covering Evolving Research, Therapeutic Innovations, and Competitive ...

wn.com - 24/Sep 00:57

DelveInsight’s “Breast Cancer Pipeline Insight 2025” report provides comprehensive insights about 250+ Breast Cancer companies and...

Les derniers communiqués